Page 15 - CUA Adv Prostate Ca Drug Acccess Listing

MANITOBA Link to Patient Assistance Programs

Funding:
CancerCare Manitoba covers in- and outpatient cost of injectable and oral treatments no matter where they are taken.

Formularies:
For oral drugs, Manitoba Home Cancer Drug Program https://www.gov.mb.ca/health/pharmacare/healthprofessionals.html

DRUG Strength, References
(Brand Name) Indication Route DIN Provincial Funding Eligibility Criteria
Manufacturer
1. MB
Pharmacare
Abiraterone • Funding unclear; not listed on: 1 Program
(Zytiga) mCRPC o MB Pharmacare Drug Formulary 2 2. MB Oral Onc
Janssen o MB List of Oral Oncology Drugs Dispensed at CCMB Drugs [8-21]
3
o Part E Exceptional Drug Status 3. MB EDS [8-
21]
1. MB
10 mg, Not
Alendronate - Part One Benefit – no therapeutic criteria attached to the benefit 1 Pharmacare
70 mg specified Program

Eligibility: 1. MB Regimen
• nmCRPC GENU-apa [2-
1
o Refer to CCMB Formulary for Criteria for Use (unable to identify public formulary 20]
listing) 2. Provincial
2
• Criteria under consideration: Funding
o In combination with ADT for the treatment of patients with CRPC who have no Summary [10-
detectable distant metastases by either CT, MRI or bone scan and who are at 20]
Not high risk of developing metastases.
nmCRPC 60 mg Tab
specified o High risk is defined as: i)PSADT ≤ 10 months, ii) CRPC demonstrated during
continuous ADT/post orchiectomy. Resistance defined as a minimum of 3 rising
PSA values at an interval of at least 1 week apart with a last PSA level of >2
Apalutamide ng/mL. Castrate levels of testosterone must be maintained throughout
(Erleada) apalutamide therapy.
Janssen o Patients should have a good performance status and no risk factors for seizures.

Treatment should continue until unacceptable toxicity or radiographic progression.

1. Provincial
Funding
Summary [10-
Not 20]
mCSPC - specified Under negotiation with manufacturer

Page 8 | © Canadian Urological Association
v.01-SEP-2021